Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial
Background - The phase III PAOLA-1/ENGOT-ov25 study (NCT02477644) showed that addition of olaparib to bevacizumab maintenance improved progression-free survival (PFS) in patients with newly diagnosed advanced ovarian cancer. We evaluated maintenance olaparib plus bevacizumab in older patients in PAO...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
March 2023
|
| In: |
European journal of cancer
Year: 2023, Jahrgang: 181, Pages: 42-52 |
| ISSN: | 1879-0852 |
| DOI: | 10.1016/j.ejca.2022.11.029 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.ejca.2022.11.029 Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S0959804922017798 
|
| Verfasserangaben: | Renaud Sabatier, Frédérique Rousseau, Florence Joly, Claire Cropet, Coline Montégut, Johanna Frindte, Saverio Cinieri, Eva M. Guerra Alía, Stephan Polterauer, Hiroyuki Yoshida, Ignace Vergote, Nicoletta Colombo, Sakari Hietanen, Rémi Largillier, Ulrich Canzler, Alain Gratet, Frederik Marmé, Laure Favier, Eric Pujade-Lauraine, Isabelle Ray-Coquard |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1854621149 | ||
| 003 | DE-627 | ||
| 005 | 20240329080211.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230808s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejca.2022.11.029 |2 doi | |
| 035 | |a (DE-627)1854621149 | ||
| 035 | |a (DE-599)KXP1854621149 | ||
| 035 | |a (OCoLC)1425213294 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Sabatier, Renaud |e VerfasserIn |0 (DE-588)1298752930 |0 (DE-627)1854621599 |4 aut | |
| 245 | 1 | 0 | |a Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial |c Renaud Sabatier, Frédérique Rousseau, Florence Joly, Claire Cropet, Coline Montégut, Johanna Frindte, Saverio Cinieri, Eva M. Guerra Alía, Stephan Polterauer, Hiroyuki Yoshida, Ignace Vergote, Nicoletta Colombo, Sakari Hietanen, Rémi Largillier, Ulrich Canzler, Alain Gratet, Frederik Marmé, Laure Favier, Eric Pujade-Lauraine, Isabelle Ray-Coquard |
| 264 | 1 | |c March 2023 | |
| 300 | |b Illustrationen | ||
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online verfügbar: 10. Dezember 2022, Artikelversion: 10. Januar 2023 | ||
| 500 | |a Gesehen am 08.08.2023 | ||
| 520 | |a Background - The phase III PAOLA-1/ENGOT-ov25 study (NCT02477644) showed that addition of olaparib to bevacizumab maintenance improved progression-free survival (PFS) in patients with newly diagnosed advanced ovarian cancer. We evaluated maintenance olaparib plus bevacizumab in older patients in PAOLA-1. - Methods - Baseline clinical and molecular data, and PFS, were compared between older (aged ≥65 years) and younger patients (<65 years). Factors associated with olaparib efficacy, and safety in age subgroups, were also assessed. - Results - Of 806 randomised patients, 292 (36.2%) were ≥65 years. A lower proportion of older versus younger patients had an Eastern Cooperative Oncology Group performance status of 0 (61.0% versus 76.2%) and upfront surgery (42.0% versus 55.7%). Older patients were less likely to have a BRCA1/2 mutation (17.1% versus 36.7%) or homologous recombination deficiency-positive status (34.1% versus 55.7%). After median follow-up of 22.1 months, median PFS was 21.6 months with olaparib versus 16.6 months with placebo in the older population (hazard ratio [HR] 0.55, 95% confidence interval [CI] 0.41-0.75), comparable with the younger population (median 22.9 versus 16.9 months; HR 0.61, 95% CI 0.49-0.77). PFS benefits were observed in patients with a BRCA mutation or homologous recombination deficiency-positive tumours. Incidence of olaparib-related grade ≥3 adverse events in older patients was comparable with that of younger patients (36.8% versus 31.7%) although hypertension and anaemia were more common in older patients. No treatment-related deaths occurred in older patients receiving olaparib. - Conclusion - Older patients enrolled in PAOLA-1 achieved similar PFS benefits compared with younger patients, with a similar safety profile. | ||
| 650 | 4 | |a Elderly | |
| 650 | 4 | |a Olaparib | |
| 650 | 4 | |a Ovarian cancer | |
| 650 | 4 | |a Safety | |
| 650 | 4 | |a Survival | |
| 700 | 1 | |a Rousseau, Frédérique |e VerfasserIn |4 aut | |
| 700 | 1 | |a Joly, Florence |e VerfasserIn |4 aut | |
| 700 | 1 | |a Cropet, Claire |e VerfasserIn |4 aut | |
| 700 | 1 | |a Montégut, Coline |e VerfasserIn |4 aut | |
| 700 | 1 | |a Frindte, Johanna |e VerfasserIn |4 aut | |
| 700 | 1 | |a Cinieri, Saverio |e VerfasserIn |4 aut | |
| 700 | 1 | |a Guerra Alía, Eva M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Polterauer, Stephan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Yoshida, Hiroyuki |e VerfasserIn |4 aut | |
| 700 | 1 | |a Vergote, Ignace |e VerfasserIn |4 aut | |
| 700 | 1 | |a Colombo, Nicoletta |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hietanen, Sakari |e VerfasserIn |4 aut | |
| 700 | 1 | |a Largillier, Rémi |e VerfasserIn |4 aut | |
| 700 | 1 | |a Canzler, Ulrich |e VerfasserIn |4 aut | |
| 700 | 1 | |a Gratet, Alain |e VerfasserIn |4 aut | |
| 700 | 1 | |a Marmé, Frederik |d 1974- |e VerfasserIn |0 (DE-588)132561972 |0 (DE-627)52394893X |0 (DE-576)299226549 |4 aut | |
| 700 | 1 | |a Favier, Laure |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pujade-Lauraine, Eric |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ray-Coquard, Isabelle |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of cancer |d Amsterdam [u.a.] : Elsevier, 1992 |g 181(2023) vom: März, Seite 42-52 |w (DE-627)266883400 |w (DE-600)1468190-0 |w (DE-576)090954173 |x 1879-0852 |7 nnas |a Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial |
| 773 | 1 | 8 | |g volume:181 |g year:2023 |g month:03 |g pages:42-52 |g extent:11 |a Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ejca.2022.11.029 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S0959804922017798 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20230808 | ||
| 993 | |a Article | ||
| 994 | |a 2023 | ||
| 998 | |g 132561972 |a Marmé, Frederik |m 132561972:Marmé, Frederik |d 60000 |d 61300 |d 50000 |e 60000PM132561972 |e 61300PM132561972 |e 50000PM132561972 |k 0/60000/ |k 1/60000/61300/ |k 0/50000/ |p 17 | ||
| 999 | |a KXP-PPN1854621149 |e 4363641843 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Renaud Sabatier, Frédérique Rousseau, Florence Joly, Claire Cropet, Coline Montégut, Johanna Frindte, Saverio Cinieri, Eva M. Guerra Alía, Stephan Polterauer, Hiroyuki Yoshida, Ignace Vergote, Nicoletta Colombo, Sakari Hietanen, Rémi Largillier, Ulrich Canzler, Alain Gratet, Frederik Marmé, Laure Favier, Eric Pujade-Lauraine, Isabelle Ray-Coquard"]},"relHost":[{"note":["Gesehen am 21.03.24","Ungezählte Beil.: Supplement"],"title":[{"title_sort":"European journal of cancer","title":"European journal of cancer"}],"pubHistory":["28.1992 -"],"origin":[{"dateIssuedDisp":"1992-","publisher":"Elsevier ; Pergamon Press","publisherPlace":"Amsterdam [u.a.] ; [Erscheinungsort nicht ermittelbar]","dateIssuedKey":"1992"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"disp":"Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trialEuropean journal of cancer","part":{"year":"2023","text":"181(2023) vom: März, Seite 42-52","volume":"181","pages":"42-52","extent":"11"},"corporate":[{"role":"isb","display":"European Organization for Research on Treatment of Cancer"},{"role":"isb","display":"European Association for Cancer Research"},{"role":"isb","display":"European School of Oncology"}],"titleAlt":[{"title":"EJC online"}],"language":["eng"],"recId":"266883400","id":{"eki":["266883400"],"issn":["1879-0852"],"zdb":["1468190-0"]}}],"recId":"1854621149","id":{"doi":["10.1016/j.ejca.2022.11.029"],"eki":["1854621149"]},"language":["eng"],"physDesc":[{"noteIll":"Illustrationen","extent":"11 S."}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"origin":[{"dateIssuedKey":"2023","dateIssuedDisp":"March 2023"}],"person":[{"display":"Sabatier, Renaud","given":"Renaud","family":"Sabatier","role":"aut"},{"given":"Frédérique","family":"Rousseau","display":"Rousseau, Frédérique","role":"aut"},{"role":"aut","family":"Joly","given":"Florence","display":"Joly, Florence"},{"given":"Claire","family":"Cropet","display":"Cropet, Claire","role":"aut"},{"role":"aut","display":"Montégut, Coline","family":"Montégut","given":"Coline"},{"display":"Frindte, Johanna","given":"Johanna","family":"Frindte","role":"aut"},{"role":"aut","family":"Cinieri","given":"Saverio","display":"Cinieri, Saverio"},{"role":"aut","display":"Guerra Alía, Eva M.","given":"Eva M.","family":"Guerra Alía"},{"display":"Polterauer, Stephan","family":"Polterauer","given":"Stephan","role":"aut"},{"role":"aut","display":"Yoshida, Hiroyuki","given":"Hiroyuki","family":"Yoshida"},{"display":"Vergote, Ignace","family":"Vergote","given":"Ignace","role":"aut"},{"role":"aut","display":"Colombo, Nicoletta","family":"Colombo","given":"Nicoletta"},{"role":"aut","family":"Hietanen","given":"Sakari","display":"Hietanen, Sakari"},{"family":"Largillier","given":"Rémi","display":"Largillier, Rémi","role":"aut"},{"role":"aut","display":"Canzler, Ulrich","given":"Ulrich","family":"Canzler"},{"role":"aut","display":"Gratet, Alain","family":"Gratet","given":"Alain"},{"display":"Marmé, Frederik","family":"Marmé","given":"Frederik","role":"aut"},{"role":"aut","given":"Laure","family":"Favier","display":"Favier, Laure"},{"role":"aut","display":"Pujade-Lauraine, Eric","family":"Pujade-Lauraine","given":"Eric"},{"display":"Ray-Coquard, Isabelle","given":"Isabelle","family":"Ray-Coquard","role":"aut"}],"title":[{"title":"Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial","title_sort":"Efficacy and safety of maintenance olaparib and bevacizumab in ovarian cancer patients aged ≥65 years from the PAOLA-1/ENGOT-ov25 trial"}],"note":["Online verfügbar: 10. Dezember 2022, Artikelversion: 10. Januar 2023","Gesehen am 08.08.2023"]} | ||
| SRT | |a SABATIERREEFFICACYAN2023 | ||